Here's how the mental health creator sustained it, and built it into a business.

The FOCUS-2 trial in children complements the recently announced FOCUS-3 trial in adolescents with ADHDNEW YORK, July 07, 2026 (GLOBE NEWSWIRE) ...

The double-blind, randomised, multicentre, placebo-controlled study aims to enrol around 468 patients.

Jen Fowler said she had learned to see how living with ADHD had helped her, rather than holding her back.

From organizing her own thoughts to working with researchers, the creator shares how her channel has evolved over the past ...

Attention deficit hyperactivity disorder (ADHD) is one of the most widely discussed neurodevelopmental conditions, yet it also remains one of the most misunderstood. Public awareness has grown ...

ADHD has had a strange run. For a long time, it was barely taken seriously — a thing restless boys supposedly grew out of, ...

The FOCUS-2 trial in children complements the recently announced FOCUS-3 trial in adolescents with ADHD NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharm ...

Quote of the day by Richard Branson believes life is too short for unhappiness and hence the billionaire advocates moving on.

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that the first patient has been ...

Yasmin Shaheen-Zaffar has struggled with ADHD her entire life, and always assumed she was unemployable. She thinks having a ...

Making the dress was a steep learning curve for Layla, who has autism, and Karen Rogers, director of Chesterfield’s ...